SCHEMBL12600129

SCHEMBL12600129

CCOC(=O)C[C@H](O[Si](C)(C)C(C)(C)C)c1ccc2ccncc2c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KCNH2 Q12809 1/20 0.35
ROCK2 O75116 10/20 0.35
NOTUM Q6P988 1/20 0.34
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
CYP26A1 O43174 1/20 0.33
BRAF P15056 1/20 0.33
DRD2 P14416 1/20 0.33
NR3C1 P04150 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12600135 0.85 CYP2D6 (0.35) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL12600127 0.85 ROCK2 (0.42) ROCK2NR3C1
SCHEMBL12600146 0.83 DRD2 (0.33) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL12600131 0.80 KDM4E (0.43) NOTUMNR3C1KDM4EALDH1A1HTT
SCHEMBL12600084 0.79 CYP2D6 (0.39) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL12600159 0.79 ROCK2 (0.33) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL22397218 0.79 DRD2 (0.35) DRD2KDM4EALDH1A1HTTTHRB
SCHEMBL2818376 0.77 TAS1R3 (0.39) KDM4ETHRB
SCHEMBL12600156 0.76 ALDH1A1 (0.41) ROCK2KDM4EALDH1A1
SCHEMBL12600052 0.76 SMN1; SMN2 (0.41) DRD2KDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935827-B2 Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto esters BAYER SCHERING PHARMA AG (DE) 2011-05-03 US disclosed
US-20100248313-A1 NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS BAYER SCHERING PHARMA AG (DE) 2010-09-30 US disclosed
US-7626035-B2 Ethyl 2-(benzothiazol-2-yl),2-oxo-acetate; useful in the synthesis of epothilonederivatives; antitumor,-carcinogenic agents; high chemical purity, optical purity,in very good yields and allows an industrial-scale production BAYER SCHERING PHARMA AG (DE) 2009-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100248313-A1 NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS CYP8B1, HSD17B7, CYP51A1 CYP2D6 379/4885SLC6A2 4684/4885SLC6A4 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.